Tag Archives: commercialization

BluePrint’s AYVAKIT and GAVRETO™ Selected Biologics and PantherRx Rare as Limited Specialty Pharmacies

Blueprint creates medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease

Fishawack Health Acquires The Hive Health Group

Fishawack Health is a leading global commercialization partner for the modern life sciences era

Trinity Acquires BluePrint Research Group Strengthening Commercialization Potential

Trinity’s approach is focused on its foundation of three: advisory services, insights & analytics, and technology

PRECISIONxtract Increasing Life Sciences Commercialization Capabilities

PRECISIONxtract bolsters its position as an industry leader in providing data-driven insights and technology-enabled solutions addressing the commercialization challenges faced by life science companies

EVERSANA Rapidly Implementing Holistic Commercialization Strategies

EVERSANA serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies

Drug Commercialization HUB Services Remain in Demand

Two Labs offers strategic consulting and commercialization business that in combination with Envision will offer value to global pharma and biotech through a combined, unique launch excellence offering

Genentech (Roche) and Blueprint Medicines Collaborate to Increase Market Access

Both Gavreto and AYVAKIT are available through Blueprint’s specialty distribution network and two specialty pharmacies: Biologics by McKesson and PantherRx

Optime Care Takes Patient-First Approach for Orphan and Rare Disorders

Optime Care offers a patient-first suite of comprehensive services tailored to maximize the therapeutic opportunities for the treatment of orphan and rare disorders